Wellington Management Group LLP Sells 26,207 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Wellington Management Group LLP lessened its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 22.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,825 shares of the company’s stock after selling 26,207 shares during the quarter. Wellington Management Group LLP owned 0.18% of Tyra Biosciences worth $2,135,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in shares of Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after acquiring an additional 2,574 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Tyra Biosciences by 2.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock worth $4,085,000 after purchasing an additional 3,792 shares during the last quarter. Ally Bridge Group NY LLC boosted its position in Tyra Biosciences by 2.0% during the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock valued at $6,349,000 after buying an additional 5,415 shares during the period. Oppenheimer & Co. Inc. grew its stake in shares of Tyra Biosciences by 9.0% during the third quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock valued at $1,806,000 after buying an additional 6,318 shares during the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Tyra Biosciences by 5.9% during the third quarter. Jennison Associates LLC now owns 158,187 shares of the company’s stock valued at $3,719,000 after buying an additional 8,837 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Insider Activity

In other Tyra Biosciences news, CEO Todd Harris sold 19,084 shares of the company’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $27.90, for a total value of $532,443.60. Following the sale, the chief executive officer now owns 1,355,927 shares in the company, valued at approximately $37,830,363.30. This represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Alan Fuhrman bought 9,500 shares of the stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $16.00 per share, with a total value of $152,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at approximately $205,584. The trade was a 283.67 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 95,352 shares of company stock worth $2,096,973 in the last quarter. 15.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on TYRA. Oppenheimer increased their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Wedbush reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Finally, HC Wainwright cut their price target on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.00.

Tyra Biosciences Stock Down 4.6 %

Shares of TYRA stock opened at $14.52 on Thursday. The firm has a market capitalization of $734.76 million, a price-to-earnings ratio of -9.02 and a beta of 1.01. The stock has a fifty day moving average of $18.36 and a 200 day moving average of $19.66. Tyra Biosciences, Inc. has a 52 week low of $11.24 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.